# Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

Source: https://onco.cc/trials/nct05720130/  
OnCo record `nct05720130` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of [²¹²Pb]Pb-ADVC001 (Phase 1b) in prostate cancer, run by AdvanCell Pty Limited, now recruiting.

## Summary

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). is a phase 1/2 interventional study registered as NCT05720130 by AdvanCell Pty Limited, with 100 participants planned, started 2023-03-15 and due to reach its primary completion in 2029-01-31. Interventions recorded: [²¹²Pb]Pb-ADVC001 (Phase 1b) and [²¹²Pb]Pb-ADVC001 (Phase 2a).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05720130
- Phase: 1/2
- Setting: Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
- Sponsor: AdvanCell Pty Limited
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05720130: https://clinicaltrials.gov/study/NCT05720130

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)

---
JSON: https://onco.cc/api/v1/entities/nct05720130.json